



UCB News

Disposal of own shares

Brussels (Belgium), 18 March 2020 – 20:00 (CET) – regulated information

In application of article 8:6 of the Royal Decree executing the new Belgian Code of Companies and Associations, UCB SA/NV announces that following exercises of stock options by its employees, it has disposed of UCB shares OTC in view of deliveries of shares to the relevant employees, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
06 March 2020	11:45:41	Stock Option Plan 2010	600	€ 31.62
06 March 2020	16:39:06	Stock Option Plan 2011	100	€ 26.72
09 March 2020	17:15:00	Stock Option Plan 2011	100	€ 26.72
10 March 2020	09:23:45	Stock Option Plan 2011	100	€ 26.72
11 March 2020	12:23:47	Stock Option Plan 2013	500	€ 48.69
11 March 2020	09:12:48	Stock Option Plan 2010	2,500	€ 31.62

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)